Drug Trial News

RSS

Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Cardiome Pharma Corp. today announced results from a Phase 3 clinical study conducted with BRINAVESS (vernakalant intravenous, RSD 1235) in the Asia-Pacific (A-P) region.

7 Nov 2014

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Neuronetrix has been selected by Anavex Life Sciences Corp. to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer's disease. Neuronetrix will be utilizing their COGNISION System to measure and analyze cognitive biomarkers in study participants.

7 Nov 2014

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's today announced the opening of patient enrollment for its new cellular immunotherapy clinical research trial designed to induce remission in children suffering from neuroblastoma, one of the deadliest forms of childhood cancer.

7 Nov 2014

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.

7 Nov 2014

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.

7 Nov 2014

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

The National Institutes of Health has boosted funding for the first large-scale clinical trial aimed at identifying drugs to stop or slow Alzheimer's disease in people destined to get the debilitating illness.

6 Nov 2014

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Janssen Research & Development, LLC today announced a collaboration with the International Union Against Tuberculosis and Lung Disease (The Union) to include SIRTURO (bedaquiline) in the STREAM Study.

6 Nov 2014

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Advaxis, Inc., a cancer immunotherapy company, today announced the abstracts of three preclinical and clinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, November 6-9, 2014 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland.

5 Nov 2014

Common drug could become the future standard of care for HE patients

A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.

4 Nov 2014

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

Patients with a specific type of oesophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results being presented at the National Cancer Research Institute (NCRI) Cancer Conference today (Wednesday).

4 Nov 2014

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca and Pharmacyclics, Inc. today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.

4 Nov 2014

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Ruthigen, Inc., announced today enrollment of the first patient in a Randomized, Double-Blind Phase 1/2 clinical trial to evaluate the safety, tolerability, and potential efficacy of its lead drug candidate, RUT58-60, for use as an adjunct to systemic antibiotics in abdominal surgery.

4 Nov 2014

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

Inventiva, a drug discovery company that focuses on therapeutic approaches involving transcription factors and epigenetic targets, today announces that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has given a positive opinion on the designation of IVA337 as an orphan medicinal product.

4 Nov 2014

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Merck Sharp & Dohme Ltd. MSD (known as Merck & Co., Inc. in the United States and Canada), today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once daily oral doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), plus tenofovir/emtricitabine (TDF/FTC) compared to efavirenz plus TDF/FTC in previously untreated patients with HIV-1 infection.

4 Nov 2014

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Transition Therapeutics Inc. ("Transition" or the "Company") today announced findings from a Phase 2 study of neuropsychiatric drug candidate, ELND005, as an adjunctive maintenance treatment for bipolar disorder type I patients (BPD).

4 Nov 2014

Eribulin drug could extend life of women with advanced triple negative breast cancer

THE cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool today (Monday).

3 Nov 2014

Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

Avanir Pharmaceuticals, Inc. today announced the publication of results from TARGET, a pivotal phase III study evaluating the efﬁcacy and safety of AVP-825 22mg in the January 2015 issue of Headache (Early access is now available).

30 Oct 2014

NCI supports further clinical development of next-generation HPV vaccine

The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine.

30 Oct 2014

New data demonstrates improved outcomes in psoriasis patients treated with Daivobet gel

Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians’ assessments of disease severity.

29 Oct 2014

Japanese mushroom extract shows promise in eradicating HPV

A Japanese mushroom extract appears to be effective for the eradication of human papillomavirus (HPV), according to a pilot clinical trial at The University of Texas Health Science Center at Houston Medical School.

29 Oct 2014

Drug Trial News

Cardiome Pharma announces results from Phase 3 clinical study of BRINAVESS

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

Olaparib shows promise for advanced cancers associated with BRCA1 and BRCA2 mutations

NIH boosts funding for first large-scale clinical trial aimed at identifying drugs for Alzheimer's

Janssen working with The Union to evaluate SIRTURO (bedaquiline) in patients with MDR-TB

Clinical study data of Advaxis' Lm-LLO immunotherapies to be presented at SITC Annual Meeting

Common drug could become the future standard of care for HE patients

Gefitinib drug boosts oesophageal cancer patients' survival by up to six months

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

Ruthigen enrolls first patient in Phase 1/2 clinical trial of RUT58-60

Inventiva’s IVA337 receives EMA COMP positive opinion on orphan drug designation for SSc treatment

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

Transition Therapeutics presents Phase 2 study of ELND005 drug for bipolar disorder

Eribulin drug could extend life of women with advanced triple negative breast cancer

Avanir Pharmaceuticals to publish AVP-825 phase III study results in the journal 'Headache'

NCI supports further clinical development of next-generation HPV vaccine

New data demonstrates improved outcomes in psoriasis patients treated with Daivobet gel

Japanese mushroom extract shows promise in eradicating HPV

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News